ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Division Spotlight
Isotopes & Radiation
Members are devoted to applying nuclear science and engineering technologies involving isotopes, radiation applications, and associated equipment in scientific research, development, and industrial processes. Their interests lie primarily in education, industrial uses, biology, medicine, and health physics. Division committees include Analytical Applications of Isotopes and Radiation, Biology and Medicine, Radiation Applications, Radiation Sources and Detection, and Thermal Power Sources.
Meeting Spotlight
2024 ANS Annual Conference
June 16–19, 2024
Las Vegas, NV|Mandalay Bay Resort and Casino
Standards Program
The Standards Committee is responsible for the development and maintenance of voluntary consensus standards that address the design, analysis, and operation of components, systems, and facilities related to the application of nuclear science and technology. Find out What’s New, check out the Standards Store, or Get Involved today!
Latest Magazine Issues
Jun 2024
Jan 2024
Latest Journal Issues
Nuclear Science and Engineering
August 2024
Nuclear Technology
July 2024
Fusion Science and Technology
Latest News
Orano Med inaugurates Pb-212 production facility in Indiana
Guillaume Dureau of Orano Group (left) and Orano Med’s Julien Dodet cut the ribbon on the new ATLabs Indianapolis. (Photo: Orano)
Orano Group subsidiary Orano Med, a developer of targeted alpha therapies for oncology, inaugurated its first ATLab (Alpha Therapy Laboratory) earlier this month. Located in Brownsburg, near Indianapolis, Ind., ATLab Indianapolis is an industrial-scale pharmaceutical facility dedicated to the production of lead-212–based radioligand therapies.
Targeted alpha therapy has shown to be effective in treating various oncological diseases, combining the natural ability of biological molecules to target cancer cells with the short-range cell-killing capabilities of alpha emissions generated by Pb-212. With a half-life of 10.64 hours, along with a decay product of the short-lived alpha-emitter bismuth-212, Pb-212 allows for the possible synthesis and purification of complex radiopharmaceuticals with minimum loss of radioactivity during preparation.
The development of radiopharmaceuticals has long been hampered by the difficulty of manufacturing and distribution on an industrial scale, Orano said, adding that the construction of ATLab Indianapolis is a major step toward making these new treatments available to cancer patients with high unmet needs in North America.
Holly R. Trellue
Nuclear Technology | Volume 147 | Number 2 | August 2004 | Pages 171-180
Technical Paper | Fuel Cycle and Management | doi.org/10.13182/NT04-A3523
Articles are hosted by Taylor and Francis Online.
The use of light water reactors (LWRs) for the destruction of plutonium and other actinides [especially those in spent nuclear fuel (SNF)] is being examined worldwide. One possibility for transmutation of this material is the use of mixed-oxide (MOX) fuel, which is a combination of uranium and plutonium oxides. MOX fuel is used in nuclear reactors worldwide, so a large experience base for its use already exists. However, to limit implementation of SNF transmutation to only a fraction of the LWRs in the United States with a reasonable number of license extensions, full cores of MOX fuel probably are required. This paper addresses the logistics associated with using LWRs for this mission and the design issues required for full cores of MOX fuel. Given limited design modifications, this paper shows that neutronic safety conditions can be met for full cores of MOX fuel with up to 8.3 wt% of plutonium.